Data presented at the 16th International Kidney Cancer Symposium showed that TP53 and VHL genes could act as predictive biomarkers for VEGF-targeted therapy for RCC.
Renal Cell Carcinoma
A new study demonstrates a relationship between radiographic tumor burden and the detection of circulating tumor DNA in patients with metastatic renal cell carcinoma.
Researchers have discovered that androgen signaling can either stimulate or suppress tumor cell movement and invasion to different locations in the body in patients who have renal cell carcinoma.
Data from three independent cohorts suggest that high EZH2 expression may mean a higher risk of death for patients with clear cell renal cell carcinoma.
Boosting NK cell infiltration into RCC tumors appears to be an attractive therapeutic option for improving the success of NK cell–based therapies and improving clinical response.
A discovery of novel biomarkers for renal cell carcinoma may lead to a diagnostic blood test that could mean earlier detection of the disease and improved patient outcomes.
The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.
Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.
Newer cancer drugs are being approved on the basis of shorter studies and on outcomes that might not predict living longer or feeling better.
Researchers from X4 Pharmaceuticals in Cambridge, Mass., have been developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T cells to track and destroy cancer.